* Corvus Pharmaceuticals Inc CRVS.OQ reported a quarterly
adjusted loss of 60 cents per share for the quarter ended
September 30, lower than the same quarter last year, when the
company reported EPS of -12 cents. The mean expectation of
five analysts for the quarter was for a loss of 11 cents per
share. Wall Street expected results to range from -14 cents
to -10 cents per share.
* Reported revenue was zero; analysts expected zero.
* Corvus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 60 cents.
* The company reported a quarterly loss of $40.22 million.
* Corvus Pharmaceuticals Inc shares had risen by 81.1% this
quarter and gained 443.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 8.5%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Corvus
Pharmaceuticals Inc is 10.00
This summary was machine generated from LSEG data November 12 at
11:28 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.11 -0.60 Missed
Jun. 30 2024 -0.11 -0.04 Beat
Mar. 31 2024 -0.13 -0.12 Beat
Dec. 31 2023 -0.12 -0.14 Missed